SGN-LIV1A: a development stage antibody drug-conjugate targeting LIV-1 for the treatment of metastatic breast cancer.

被引：3
|
作者：
Sussman, Django [1 ]
Smith, Leia M. [1 ]
Anderson, Martha E. [1 ]
Duniho, Steve [1 ]
Hunter, Joshua H. [1 ]
Kostner, Heather [1 ]
Miyamoto, Jamie B. [1 ]
Nesterova, Albina [1 ]
Westendorf, Lori [1 ]
Van Epps, Heather A. [1 ]
Whiting, Nancy [1 ]
Benjamin, Dennis R. [1 ]
机构：
[1] Seattle Genet, Bothell, WA USA
来源：
CANCER RESEARCH | 2013年 / 73卷 / 08期
关键词：
D O I：
10.1158/1538-7445.AM2013-3962
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3962
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Development of CDCP1-targeting antibody-drug conjugate for Triple negative and metastatic breast cancer
    Gough, Madeline
    Khan, Tashbib
    Kwah, Kayden
    He, Yaowu
    Ratnayake, Gishan
    Pyke, Christopher
    Snell, Cameron
    Hooper, John
    Kryza, Thomas
    CANCER RESEARCH, 2023, 83 (05)
  • [22] LIV-1 and Trop2 expression using Immunohistochemistry as prognostic markers in early breast cancer
    Choi, Yeonjoo
    Ryu, Han Suk
    Koh, Jiwon
    Lee, Dae-Won
    Lee, Kyung-hun
    Im, Seock-Ah
    CANCER RESEARCH, 2024, 84 (09)
  • [23] Expression levels of the putative zinc transporter LIV-1 are associated with a better outcome of breast cancer patients
    Kasper, G
    Weiser, AA
    Rump, A
    Sparbier, K
    Dahl, E
    Hartmann, A
    Wild, P
    Schwidetzky, U
    Castaños-Velez, E
    Lehmann, K
    INTERNATIONAL JOURNAL OF CANCER, 2005, 117 (06) : 961 - 973
  • [24] BRY812, an anti-LIV-1 antibody drug conjugate with novel conjugation method for cancer therapeutics
    Zhao, Xiaobei
    Zhu, Jie
    Zhou, Yaqiong
    Li, Jing
    Nie, Lei
    Wang, Haibin
    Chen, Gang
    CANCER RESEARCH, 2024, 84 (06)
  • [25] Evaluation of SGN-LIV1a followed by AC in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL
    Beckwith, Heather
    Schwab, Richard
    Yau, Christina
    Stringer-Reasor, Erica
    Wei, Shi
    Chien, A. Jo
    Albain, Kathy S.
    Kalinsky, Kevin
    Wallace, Anne
    Elias, Anthony
    Yee, Douglas
    Clark, Amy S.
    Boughey, Judy C.
    Han, Heather
    Nanda, Rita
    Isaacs, Claudine
    Mitri, Zahi
    Lang, Julie E.
    Thomas, Alexandra
    Sanft, Tara
    DeMichele, Angela
    Perlmutter, Jane
    Rugo, Hope S.
    Hylton, Nola M.
    Symmans, W. Fraser
    Melisko, Michelle E.
    van't Veer, Laura J.
    Wilson, Amy
    Asare, Smita M.
    Sanil, Ashish
    Berry, Donald A.
    Esserman, Laura J.
    CANCER RESEARCH, 2021, 81 (04)
  • [26] Concordant correlation of LIV-1 and E-cadherin expression in human breast cancer cell MCF-7
    Hui Shen
    Haihong Qin
    Junsheng Guo
    Molecular Biology Reports, 2009, 36 : 653 - 659
  • [27] Concordant correlation of LIV-1 and E-cadherin expression in human breast cancer cell MCF-7
    Shen, Hui
    Qin, Haihong
    Guo, Junsheng
    MOLECULAR BIOLOGY REPORTS, 2009, 36 (04) : 653 - 659
  • [28] Structure-function analysis of LIV-1, the breast cancer-associated protein that belongs to a new subfamily of zinc transporters
    Taylor, KM
    Morgan, HE
    Johnson, A
    Hadley, LJ
    Nicholson, RI
    BIOCHEMICAL JOURNAL, 2003, 375 : 51 - 59
  • [29] Development of antibody-drug conjugates targeting the CDCP1 receptor for the treatment of Triple negative and metastatic breast cancer
    Gough, M.
    Kwah, K.
    Khan, T.
    He, Y.
    Pyke, C.
    Ratnayake, G.
    Snell, C.
    Hooper, J.
    Kryza, T.
    EUROPEAN JOURNAL OF CANCER, 2022, 175 : S81 - S82
  • [30] The regulation of LIV-1 mRNA in MDA-MB-231 human breast cancer cells and its association with E-cadherin
    Chong, Leelyn
    Sankavaram, Kavitha
    Freake, Hedley C.
    FASEB JOURNAL, 2010, 24
12345